Dr Reddys Laboratories (RDY) EBT Margin (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported EBT Margin for 15 consecutive years, with 27.78% the latest figure, recorded in Q2 2023.

• Quarterly EBT Margin changed N/A year-over-year to 27.78% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 0.0% (changed N/A YoY) and the FY2026 annual result came in at 16.31%, down 730.0% from the prior year.
• EBT Margin steadied at 27.78% in Q2 2023 per RDY's latest filing, from 27.74% in the prior quarter.
• Over the last five years, EBT Margin for RDY reached as high as 27.78% in Q2 2023 and fell as low as 10.67% in Q3 2020.
• A 5-year average of 17.43% and a median of 19.97% in 2020 frame the typical range for EBT Margin.
• Annual changes were most pronounced in 2019 — EBT Margin jumped 861 bps — and 2020, when it sank 2386 bps.
• Year by year, EBT Margin stood at 13.19% in 2019, then plunged by 181 bps to 10.67% in 2020, then soared by 306 bps to 22.01% in 2021, then fell by 4 bps to 21.12% in 2022, then jumped by 32 bps to 27.78% in 2023.
• According to Business Quant data, EBT Margin over the past three periods registered 27.78%, 27.74%, and 21.12% for Q2 2023, Q1 2023, and Q4 2022 respectively.